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Abstract
The canary pox vector and gp120 vaccine (ALVAC-HIV and AIDSVAX B/E gp120) in the
RV144 HIV-1 vaccine trial conferred an estimated 31% vaccine efficacy. Although the
vaccine Env AE.A244 gp120 is antigenic for the unmutated common ancestor of V1V2
broadly neutralizing antibody (bnAbs), no plasma bnAb activity was induced. The RV305
(NCT01435135) HIV-1 clinical trial was a placebo-controlled randomized double-blinded
study that assessed the safety and efficacy of vaccine boosting on B cell repertoires. HIV-1-
uninfected RV144 vaccine recipients were reimmunized 6–8 years later with AIDSVAX B/E
gp120 alone, ALVAC-HIV alone, or a combination of ALVAC-HIV and AIDSVAX B/E gp120
in the RV305 trial. Env-specific post-RV144 and RV305 boost memory B cell VH mutation
frequencies increased from 2.9% post-RV144 to 6.7% post-RV305. The vaccine was well
tolerated with no adverse events reports. While post-boost plasma did not have bnAb activ-
ity, the vaccine boosts expanded a pool of envelope CD4 binding site (bs)-reactive memory
B cells with long third heavy chain complementarity determining regions (HCDR3) whose
germline precursors and affinity matured B cell clonal lineage members neutralized the HIV-
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1 CRF01 AE tier 2 (difficult to neutralize) primary isolate, CNE8. Electron microscopy of two
of these antibodies bound with near-native gp140 trimers showed that they recognized an
open conformation of the Env trimer. Although late boosting of RV144 vaccinees expanded
a novel pool of neutralizing B cell clonal lineages, we hypothesize that boosts with stably
closed trimers would be necessary to elicit antibodies with greater breadth of tier 2 HIV-1
strains.
Trial Registration: ClinicalTrials.gov NCT01435135
Author summary
Developing a successful HIV-1 vaccine remains a high global health priority. Several HIV-
1 vaccine trials have been performed with only the RV144 vaccine trial showing vaccine
efficacy, albeit modest. No broadly neutralizing antibody activity was identified in RV144
and inducing sterilizing immunity against a complex pathogen like HIV-1 remains a
major challenge. Here we characterize the B cell responses after RV144 vaccine-recipients
received two additional boosts severals years after the conclusion of the RV144 vaccine
trial. Delayed and repetitive boosting of RV144 vaccine-recipients was capable of increas-
ing somatic hypermutation of the Env-reactive antibodies and expanding subdominant
pools of neutralizing B cell clonal lineages. These data are pertinent to HIV-1 vaccine-regi-
men design.
Introduction
Six HIV-1 vaccine efficacy trials have been performed [1–5], of which only one, the ALVA-
C-HIV and AIDSVAX B/E prime-boost RV144 trial, showed vaccine protection, with esti-
mated vaccine efficacies of 60% at 12 months [6] and 31% at 42 months [7]. Plasma IgG
antibodies binding to HIV-1 envelope variable region 2 (V2) and low Env IgA binding levels
were immune correlates of decreased transmission risk [8]. V2-specific antibodies isolated
from RV144 bound tier 2 HIV-1 infected CD4 T cells and mediated antibody dependent cellu-
lar cytotoxicity (ADCC) [9].
While no broadly neutralizing antibodies (bnAbs) were induced in RV144 [8,10] the induc-
tion of bnAbs remains a prime goal of HIV vaccine development, since passive administration
of bnAbs has repeatedly shown to protect against simian HIV-1 (SHIV) chimeric virus chal-
lenge [11–15]. BnAbs develop in approximately 50% of HIV-1 infected individuals, but these
arise only after several years of infection [16,17]. One hypothesis to explain why HIV-1 bnAbs
have been difficult to induce by vaccination is that these antibodies have one or more unusual
characteristic—long HCDR3 regions, autoreactivity with host antigens, and/or extensive
somatic mutations—all traits of antibodies controlled by host tolerance control mechanisms
[18–22]. A result of tolerance control of bnAbs is that bnAb precursors may be reduced in fre-
quency in the pre-vaccination B cell repertoire; they may also be at a competitive disadvantage
with other more dominant precursor B cell pools. For these reasons, inducing bnAbs may
require an extensive vaccination-regimen.
Here we sought to determine if a pool of subdominant B cells, such as those that produce
long HCDR3 CD4 bs bnAbs, may be expanded when an Env immunogen that binds bnAb
UCAs is included in a boosting regimen. In the RV305 clinical trial, RV144 vaccine-recipients
who had previously received the initial ALVAC-HIV + AIDSVAX B/E gp120 immunization
Vaccine-induced HIV-1 CD4 binding site neutralizing antibodies
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regimen (0,1,3,6 months) and remained HIV-1- uninfected were boosted with ALVAC-HIV,
AIDSVAX B/E gp120, or ALVAC-HIV + AIDSVAX B/E gp120 6–8 years later (S1 Fig). We
found that boosting of RV144 vaccinees led to an increased frequency of memory B cells pro-
ducing envelope-specific antibodies with long HCDR3s. Several of the mature antibodies and
inferred unmutated common ancestors (UCA) neutralized both neutralization sensitive HIV-
1 isolates (tier 1) and a difficult-to-neutralize (tier 2) HIV-1 CRF01 AE isolate, CNE8.
Results
AIDSVAX B/E gp120 boosted antibodies with long HCDR3 regions
After two boosts (6-month interval) with the same immunogens 6–8 years after the completion
of the RV144 primary immunizations (S1 Fig), plasma neutralizing antibody (nAb) responses
were assayed in the A3R5 pseudovirus neutralization assay [23] against a panel of 11 CRF01
AE isolates (S2A Fig). Previous work has shown that neutralization of neutralization resistant
(tier 2) HIV-1 isolates by antibodies is more readily detected in the A3R5 cell based assay than
in the TZM-bl cell based assay [23]. Here the A3R5 cell based assay was used to search for vac-
cinees who had robust antibody responses to Env. We selected four vaccinees for study who
had high magnitude and breadth of neutralization. Two were from RV305 Group 1 who
received ALVAC-HIV plus AIDSVAX B/E gp120 boosts (3043, 3070), and two were from
RV305 Group 2 who received only AIDSVAX B/E gp120 boosts (3064, 3053) (S2B Fig). In all
four vaccinees, the RV305 boosts increased both autologous (AE.A244gp120) and heterolo-
gous (B.6240gp120) plasma IgG-gp120 binding responses, to levels higher than those observed
after the initial RV144 regimen (S3A Fig) The RV305 boosts also increased the magnitude of
B.MN and AE.92TH023 neutralization in the TZM-bl neutralization assay by plasma from all
four vaccinees, but there was no plasma tier 2 neutralizing activity seen (S3B Fig).
We isolated AE.A244 gp120 Env-specific post-RV305 boost memory B cells from the four
vaccinees- 3043, 3070, 3064 and 3053 (S4 Fig) and from the same vaccinees post-RV144 sam-
ples for three of the four vaccinees for whom PBMCs were available. Comparison of the
gp120-reactive mAbs from post-RV144 (n = 184 mAbs) with the gp120-reactive mAbs from
post-RV305 (n = 242 mAbs) showed that the mean VH nucleotide mutation frequency
increased over 2-fold in each vaccinee from a mean of 3.1% to 6.9% (Fig 1A and 1C).
Mobilizing and expanding the pool of long HCDR3 antibodies will be critical for the even-
tual induction of V2-glycan, V3-glycan, or HCDR3-loop binding bnAbs since many of these
bnAbs have HCDR3s longer than 22 amino acids (aa) [24–28]. A meta-analysis of antibodies
isolated from post-RV144 studies found that the frequency of Env-reactive B cells with
HCDR3s 22 aa was 2.1%. An analysis of the post-RV305 antibodies indicated that the fre-
quency of Env-reactive B cells with HCDR3s 22 aa was 20.7% (S5 Fig). To confirm that the
increased frequency of Env-reactive long HCDR3 mAbs was related to late boosting, we ana-
lyzed the B cell repertoires of three of the four vaccinees (3043, 3053 and 3064) for whom
blood samples were available both 2 weeks after the initial RV144 immunization and 2 weeks
after the RV305 immunizations. The average frequency of Env-reactive long HCDR3 antibod-
ies within the same vaccinees increased from 7.6% to 20.7%. (Fig 1B and 1D). The HCDR3
length is dictated primarily by V(D)J recombination and can be diversified through secondary
means: VH replacement, D-D fusion, insertions, N-nucleotide addition and P-nucelotide
addition. Long HCDR3 antibodies have been shown to be biased towards DH2, DH3 gene and
JH6 gene segment usage [29]. Coinciding with this observation 72% of the Env-reactive long
HCDR3 antibodies isolated post-RV305 and utilized DH2 or DH3 and 58% used JH6 (S1
Table). To determine if this phenomenon was unique to B cell repertoires from late boosting
of RV144 vaccinees, we compared these data with the frequency of Env-reactive long HCDR3
Vaccine-induced HIV-1 CD4 binding site neutralizing antibodies
PLOS Pathogens | DOI:10.1371/journal.ppat.1006182 February 24, 2017 3 / 21
found in other HIV-1 Env based immunization regimens. In the GSK PRO HIV-002 human
clinical trial, vaccine-recipients received gp120 immunizations in AS01B adjuvant, and the fre-
quency of Env-reactive mAbs with long HCDR3s was 6.9% (n = 58) [30]. In the DNA prime
Ad5 boost HIV-1 vaccine regimen used in the HVTN 505 efficacy trial, the frequency of
gp140-reactive mAbs with long HCDR3s was 4.1% [31] (S2 Table p< 0.05 compared to RV305
boost data; Fisher’s Exact Test). These data suggested that other immunization regimens with-
out boosting did not expand memory B cell pools with long HCDR3s to the extent achieved
with the RV305 boosts.
In vaccinee 3053, seven gp120-reactive B cell clonal lineages were present after the initial
RV144 vaccine regimen that persisted and had expanded after boosting 6–8 years later in
Fig 1. Boosting of RV144 vaccinees increased VH chain gene mutation frequency and caused a repertoire shift, increasing the
frequency of antibodies with Heavy Chain Complementary Determinant Region 3 (HCDR3) 22 amino acids. PBMCs from four
vaccinees post-RV144 (A&B) and post-RV305 (C&D) were antigen-specific single-cell sorted with fluorophore labeled conjugates. The
VH/VL chain genes were PCR-amplified and screened for Env-reactivity by ELISA. The VH chain gene mutation frequency and HCDR3
lengths of 145 Env-reactive antibodies from RV135/144 and 242 Env-reactive antibodies from RV305 were analyzed with Cloanalyst[56].
(A&C) Error bars represent the standard error of the mean.
doi:10.1371/journal.ppat.1006182.g001
Vaccine-induced HIV-1 CD4 binding site neutralizing antibodies
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RV305, one of which, DH678, had a long HCDR3. In vaccinee 3043 nine gp120-reactive B cell
clonal lineages were identified after RV144 that were also represented in the samples taken
after the RV305 boosts. The antibodies in two of these lineages, DH686 and DH576, had long
HCDR3s (S6 Fig). These data demonstrate that memory B cells producing antibodies with
long HCDR3s were induced by the initial RV144 regimen and could be expanded with boost-
ing 6–8 years later.
Epitope mapping of gp120-reactive long HCDR3 antibodies
All antibodies isolated were assayed by ELISA as transient transfection supernatants and we
selected twenty-seven Env-binding antibodies derived from blood memory B cells post-RV305
boosts based on HCDR3-length ( 22 aa) as a representative set of antibodies for characteriza-
tion (S3 Table). Nine of the 27 mAbs neutralized the neutralization sensitive (tier-1) virus
AE.92TH023 in the TZM-bl neutralization assay [23,32,33](S4 Table). The epitopes of these
nine neutralizing mAbs with long HCDR3s were then mapped by ELISA for activity in block-
ing soluble (s) CD4 binding to Env and for binding to mutant Envs. All 9 long-HCDR3 anti-
bodies that neutralized HIV-1 blocked sCD4 binding by70% (Fig 2A) and also blocked
binding of CD4 bs bnAbs VRC01 and CH31 (S7 Fig).
Env mutations I371, P363, R476 and D368 generally reduce binding by CD4bs Abs [34].
When assayed with Δ371I/P363N and D368R CD4bs Env mutants, binding of three neutral-
izing mAbs (DH576, DH576.2, and DH577) was measurably lower compared to wild-
type Env (Fig 2B). Seven of nine long HCDR3 sCD4 blocking mAbs (Fig 2A) bound to B.
YU2gp120. The binding epitopes of these seven mAbs were mapped by yeast display using
B.YU2gp120 core (ΔV1, V2, V3 loops) and B.YU2gp120 cores with mutations that reduce
binding by known CD4bs Abs [35]. In contrast to epitope mapping on A244gp120 Env
binding of six of seven mAbs were D368R sensitive (Fig 2C). The four Abs not sensitive to
the D368R mutation in A244gp120 likely have a higher affinity for the A244gp120 protein
then YU2gp120 and their epitope is less dependent on Env D368. Abs DH576 and DH576.2
shared with the CD4bs bnAb B12 sensitivity to 3 CD4bs-critical mutations (D368R, R419G,
T455E) and 2 of 3 additional mutation sensitivities (K282V and I467K) [36,37] suggesting
these vaccine-induced CD4bs mAbs have a specificity more similar to that of B12 than to
that of the non-bnAb CD4bs mAb, B6 which is not sensitive to D368R, R419G and T455E
mutations (Fig 2C).
In the TZM-bl cell assay, all neutralizing CD4bs mAbs neutralized not only AE.92TH023
but also the heterologous tier 2 CRF01 isolate AE.CNE8 isolate. DH583 was the broadest neu-
tralizing antibody, also neutralizing the tier 1 viruses B.SF162, B.MN, and the tier 1B (interme-
diate neutralization sensitivity) primary isolate C.6644 (Fig 2D). Long HCDR3 neutralizing
mAbs were assayed against four additional tier 2 CRF01 AE isolates but showed no additional
neutralization breadth (S5 Table).
In RV144, infection risk correlated inversely with V1V2 antibody responses [8]. Two V1V2
binding antibodies, CH58 and CH59, neutralized the autologous tier 1 isolate AE.92TH023 in
the TZM-bl neutralization assay and also mediated ADCC against tier 2 virus infected cells
[9]. To determine whether the long HCDR3 CD4bs mAbs isolated after the RV305 boosts also
mediated ADCC, the Abs were expressed in an IgG1 backbone optimized for FcγRIIIa binding
[38] and assayed for ADCC against virus-infected cells. DH583 mediated ADCC against B.
WITO and C.1086C virus infected cells, with an endpoint concentration of approximately
0.1μg/ml and overall ADCC activity, as evaluated by positive area under the dilution curve,
similar to that observed for the CD4bs bnAb CH31. The other eight long HCDR3 CD4 bs
mAbs had little to no ADCC activity against any of the isolates tested (S8 Fig).
Vaccine-induced HIV-1 CD4 binding site neutralizing antibodies
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The germline precursors of vaccine-induced long HCDR3 CD4bs
antibodies neutralize the tier 2 HIV-1 strain, CRF01 AE.CNE8
The most heavily mutated member of the long HCDR3 CD4bs DH576 B cell clonal lineage
was DH576.2 (VH nucleotide mutations of 10.33%), but the additional mutations did not
broaden or strengthen HIV-1 tier 2 CRF01 AE.CNE8 neutralization (Fig 2) with respect to
neutralization by less mutated lineage members such as DH576 (VH mutations of 7.33%) (S3
Table). To determine the effects of affinity maturation, we assayed the UCA, IAs and three nat-
urally occurring DH576 clonal lineage mAbs for neutralization of the autologous tier 1 virus
AE.92TH023 and the heterologous tier 2 virus CRF01 AE.CNE8. The DH576 UCA neutralized
both the tier 1 HIV-1 AE.92TH023 and the tier 2 HIV-1 CRF01 AE.CNE8. As affinity matura-
tion progressed, there was a difference in the ratio of neutralization potencies for tier 1 and
tier 2 viruses. Affinity maturation increased DH576 ineage neutralization potency (IC50)
Fig 2. The long Heavy Chain Determinant Region 3 (HCDR3) antibodies that neutralize virus bind the CD4 binding site (CD4 bs).
Purified recombinant monoclonal antibodies (mAbs) were assayed by ELISA for (A) blocking the binding of soluble CD4 to AE.A244gp120,
and (B) sensitivity to the CD4 binding site mutations Δ371I/P363N, D368R, N276A, and T278A in the AE.A244gp120 protein. (C) Epitope
mapping of mAbs on yeast displayed YU2gp120 with point mutations within the inner domain, outer domain and CD4 binding site. (D)
Assaying the long HCDR3 CD4 bs antibodies for HIV-1 neutralization in the TZM-bl neutralization assay.
doi:10.1371/journal.ppat.1006182.g002
Vaccine-induced HIV-1 CD4 binding site neutralizing antibodies
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against the tier 1 AE.92TH023 by over 3 logs, but increased its potency (IC50) against the tier 2
AE.CNE8 by less than 1 log (Fig 3). These data can be explained in part as follows. The UCA of
DH576 had a higher affinity for AE.CNE8gp120 than did the UCA for AE.A244gp120 (nearly
identical in sequence to AE.92TH023). Binding assays to the two gp120s showed affinity matu-
ration of< 1 log to AE.CNE8gp120 while there was > 2 log increase in affinity maturartion
for AE.A244gp120 (S6 Table).
To determine whether neutralization of HIV by a UCA was a common property of
HCDR3-loop CD4 bs binding mAbs, we assayed the UCAs of the other vaccine-induced
CD4bs mAbs and found that 3 of 8 nAb UCAs neutralized both AE.92TH023 and AE.CNE8
(S7 Table).These data indicated that the vaccination regimens in both RV144 and RV305 trials
could elicit long HCDR3 CD4bs mAbs, whose germline genes could mediate tier 2 neutraliza-
tion of HIV-1 AE.CNE8.
Structural analysis of long HCDR3 vaccine-induced CD4bs antibodies
Progression from sporadic tier 2 neutralization to increased tier 2 virus neutralization breadth
depends upon the epitope specificity [39] and the precise footprint of the Ab on Env [26]. We
analyzed by negative stain electron microscopy (EM) a CH505 SOSIP.664 trimer bound with
DH576. A 3D reconstruction showed DH576 bound to an open trimer—that is, to Env in a
conformation related to the one stabilized by CD4 binding (Fig 4A, S9 Fig). A top view of the
complex suggested that the DH576 footprint might resemble those of bnAbs B12 and CH103
(Fig 4B). The bnAbs CH103, CH235, CH31, VRC01, and PGV04, as well as CD4 itself, project
away from the center of the trimer, avoiding interference with adjacent gp120 subunits in the
closed trimer conformation, whereas DH576 may require the open form in order to avoid
overlap. The DH576 Fab has an orientation with respect to Env quite similar to that of the B12
Fab, but turned by ~90˚ about its long axis (Fig 4B).
Fig 3. Neutralization of the tier 1 HIV-1 isolate AE.92TH023 and the tier 2 HIV-1 isolate CRF_01 AE.CNE8 by the DH576
Unmutated Common Ancestor (UCA) and DH576 lineage members. The DH576 clonal lineage was inferred with
Cloanalyst[56]. The DH576 clonal lineage was assayed for neutralization of the tier 1 isolate AE.92TH023 and the tier 2 isolate
CRF_01 AE.CNE8 in the TZM-bl neutralization assay. Affinity maturation of the DH576 clonal lineage improved neutralization
for the tier 1 isolate AE.92TH023 by > 3 logs and for the tier 2 isolate CRF_01 AE.CNE8 by approximately 1 log.
doi:10.1371/journal.ppat.1006182.g003
Vaccine-induced HIV-1 CD4 binding site neutralizing antibodies
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The CD4bs bnAb B12 interaction with gp120 depends upon an aromatic residue at the
apex of the HCDR3 loop, aromatic residues around the base of the HCDR3 region, a tyrosine
at the apex of the HCDR2 loop and positively charged amino acids in the LCDR1[40]. An
alignment of the DH576 inferred UCA and naturally occurring clonal lineage members with
the B12 heavy sequence showed that, like B12, the DH576 clonal lineage contained an aromatic
residue at the apex of the HCDR3 loop, aromatic residues around the base of the HCDR3 and
a tyrosine in the HCDR2 loop (S10 Fig). The HCDR3s of B12 and DH576 protrude at different
angles and when DH576 is superimposed on the B12-gp120 complex, the HCDR3 of DH576
sterically clashes with gp120. Thus it is not suprising that DH576 rotates by approximately
~90˚ when it binds to gp120 (S10 Fig).
Negative stain EM of 92Br SOSIP.664 with DH583, the broadest mAb identified, showed
that DH583 also binds an open form of the trimer, even though this trimer is stable in the
closed form (S11 Fig). These observations suggest that antibodies elicited in the RV305 trial
bind epitopes generally shielded in closed trimers, consistent with the use of gp120 (rather
than a closed Env trimer) as a principal component of the original, RV144 vaccine.
Fig 4. Negative stained electron microscopy of DH576 in complex with CH505 SOSIP.664. (A) 2D class averages of one, two, or
three DH576 Fabs bound to the trimer and (B) Side and top views of the 3D EM reconstruction with the indicated Ab or sCD4 superimposed
on the gp120 subunit for comparison with DH576 binding. Arrows indicate the angle at which the indicated antibody approaches the trimer.
doi:10.1371/journal.ppat.1006182.g004
Vaccine-induced HIV-1 CD4 binding site neutralizing antibodies
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Discussion
In this paper we demonstrate that late (6–8 year) boosting of RV144 vaccinees with ALVA-
C-HIV and AIDSVAX gp120 B/E increased the VH chain gene mutation frequency and
expanded clonal lineages of CD4bs antibodies with long HCDR3 regions. Increased somatic
hypermutation and affinity maturation by repetitive immunization with a gp120-protein has
previously been reported in humans and non-human primates [30,41]. In this study the boost-
ing of RV144 vaccinees occurred several years later suggesting that in spite of the rapid waning
in plasma IgG seen in the RV144 vaccine trial, long lived memory B cells were induced that
could be recalled with subsequent boosting. The observation that three CD4bs clonal lineage
UCAs could neutralize tier 2 CRF01 AE AE.CNE8 raised the hypothesis that the AE.A244
gp120 Env in the boost selectively stimulated expansion of a pool of pre-existing tier 2 neutral-
izing clonal lineages. An antibody HCDR3 arises from recombination of immunoglobulin
heavy variable (VH), diversity (DH), and joining (JH) genes; its overall length is determined by
gene usage [20,29,42], D-D fusion [25,42,43], N nucleotide additions [22,42], or VH gene
replacement [44,45]. While B cells that give rise to long HCDR3 antibodies frequently undergo
productive gene rearrangement [42], they can experience negative selection during B cell
development because of autoreactivity or polyreactivity [21,22]. Thus, in uninfected individu-
als, only approximately 4% of the naïve repertoire consists of long HCDR3 antibodies, and this
population contracts by ~ 50% due to negative selection in the bone marrow at the first
immune tolerance checkpoint [22,29].
Virus neutralization by a fully reverted, inferred UCA has been reported for V1V2 and
CD4bs bnAbs [25,46–49] that came from HIV-1 chronically infected individuals. Pancera et al
[49] and Bonsignori et al [25] found that V1V2 bnAb UCAs of PG16 and CH01 could neutral-
ize several primary HIV strains. Both UCAs neutralized clade C ZM233, clade A AQ23 and
clade B WITO[25,49]. More recently Gorman et al [47] and Andrabi et al [48] have shown that
the combining sites of multiple V1V2 bnAbs share binding motifs, and their UCAs frequently
neutralize the same HIV-1 primary isolates, suggesting that these primary isolate Envs might
be candidates for use as immunogens.
The fundamental question raised is whether the CD4bs B cell clonal lineages primed by
RV144 and expanded with the repetitive boost of the same vaccine can, with continued boost-
ing, affinity mature into bnAbs. The epitopes of the vaccine-induced CD4bs mAbs described
here appear to overlap those of other CD4bs antibodies and that of bnAb B12 in particular.
Electron microscopy of negatively stained complexes showed that the vaccine-induced mAbs
DH576 and DH583 bound an open form of Env, consistent with a gp120 being used in the vac-
cine-regimen, and the images were consistent with the CD4bs epitope mapping. Seven of the
nine long HCDR3 CD4bs mAbs characterized here had the same VH3 gene usage as the CD4
bs bnAbs CH98 [36] and HJ16[50]; one of the nine used VH1-69 (S3 Table), like VRC13 [26].
One mAb also used a VL κ4–1 like HJ16 and six of the nine long HCDR3 CD4 bs mAbs used
either a VL κ3–20 or VL κ1–33, which are VL chain genes used by the CD4bs bnAbs B12,
VRC01, VRC-PGV04, VRC30-34, 3BNC117, 3BNC60, NIH45-46, 12A12, 12A21 and
8ANC131 (reviewed in [16]). Nonethless, after 6–8 years and 4 boosts, the induced mAbs neu-
tralized only 1 of 40 tier 2 viruses that were assayed with DH583 and DH576. Moreover, the
neutralizing IC50 of the DH576 clonal lineage for CRF01 AE.CNE8 changed only marginally
during affinity maturation, strongly suggesting that theAE.A244gp120, although it could bind
to the UCA, did not select clonal lineage members that could undergo affinity maturation and
exhibit greater breadth. Rather it was only neutralization of the tier 1 virus AE.92TH023 for
which vaccine boosting led to a 3 log increase in IC50. Thus, it is likely that AE.A244 gp120
selected antibody responses that neutralized viruses with an “open” Env conformation,
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consistent with known conformational properties of the free gp120 fragment. As previously
shown in non-human primates antibodies that exclusively bind an open Env sterically clash
with Env variable regions leaving little chance of maturing to a bnAb [51,52]. We do not yet
know whether a de novo series of prime-boost immunizations with stable, closed trimer as
proposed by others [51,53,54] would engage the UCAs of long HCDR3 antibodies such as
DH576 and induce affinity maturation to neutralization breadth. In general, Envs of tier 1
viruses open readily, while those of tier 2 viruses do not. The Env of CRF01 AE.CNE8 appar-
ently opens readily enough to bind the antibodies we have characterized, but most other tier 2
Envs do not. The boosts that expanded the pool of long HCDR3 mAbs occurred several years
after the completion of the RV144 trial. We do not know what effect the interval between
boosting has on the vaccine-induced antibody repertoire. In the RV306 HIV-1 clinical trial
(NCT01931358), vaccine-recipients received the same ALVAC-HIV and AIDSVAX B/E
prime-boost regimen and were boosted again with a shorter rest period. Characterization of
the Env-reactive mAb repertoire in these vaccine-recipients may provide some insight into
whether the length of the rest period necessary for expansion of long HCDR3 mAbs.
In summary, study of the B cell repertoires of memory B cells induced by the RV305 trial
vaccine-regimen has defined a set of CD4bs-reactive B cell clonal lineages that were initiated
by the RV144 vaccine-regimen and expanded after late boosting with the ALVAC-HIV and
AIDSVAX B/E immunogens. These antibodies derived from UCAs with some degree of tier 2
virus neutralization capability.
Materials and methods
Ethics statement
The RV305 clinical trial (NCT01435135) received approvals from Walter Reed Army Institute
of Research, Thai Ministry of Public Health, Royal Thai Army Medical Department, Faculty of
Tropical Medicine, Mahidol University, Chulalongkorn University Faculty of Medicine, and
Siriraj Hospital. Written informed consent was obtained from all clinical trial participants.The
Duke University Health System Institutional Review Board approved all human specimen
handling.
Donor subjects
The RV305 clinical trial (NCT01435135) was a randomized double blinded placebo-controlled
boosting of 162 RV144 clinical trial participants (NCT00223080) that occurred in Thailand.
The RV305 clinical trial was sponsored by the U.S. Army Office of the Surgeon General and
conducted in collaboration with the U.S. Army Medical Research and Materiel Command and
the Thailand Ministry of Public Health. The primary objective was to characterize the cellular
and humoral immune response after boosting and to evaluate the safety and tolerability of late
and repetitive boosting with the ALVAC-HIV (vCP1521) and AIDSVAX B/E immunogens.
Six-eight years after the conclusion of RV144, RV305 volunteers were randomized into three
groups and boosted two times with a six month interval with either AIDSVAX B/E + ALVAV-
HIV (vCP1521), AIDSVAX B/E or ALVAC-HIV (vCP1521) or a placebo. After commence-
ment no changes were made to the vaccine-regimen. All HIV-1 uninfected RV144 participants
that had completed the full RV144 vaccine-regimen, were at low risk for HIV-1 infection
based on self-reported behavioral habits, able to pass a Test of Understanding, gave written
consent and were in general good health were eligible. Female volunteers had to be on ade-
quate birth control 45 days prior to the first inject and consent to remaining on birth control.
For safety reasons women that were pregnant, nursing or planning on becoming pregnant
were excluded. Volunteers with a conflict of interest, psychological or medical conditions, or
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those unable to complete a Test of Understanding were excluded. Vaccine safety was measured
by self-reporting on a diary card local and systemic reactions for three days post-vaccination.
All adverse events and serious adverse events were recorded throughout the trial and up to
three months post final boost.
Antigen-specific single-cell sorting
Peripheral blood mononuclear cells (PBMCs) were stained with Aqua vital dye ((AqVd) Invi-
trogen), IgM-FITC, IgD-PE, CD3 -PECy5, CD14-BV605, CD16-BV570, CD235a-PECy5,
CD27-PECy7, CD38-APC-AF700, CD19-APCCy7, along with AF647 and BV421 conjugated
antigens. Viable antigen-specific B cells (AqVd-CD14-CD16-CD3-CD235a-CD19+IgD-
CD38all, AF647 and BV421 double positive) were single-cell sorted with a BD FACSAria II-
SORP (BD Biosciences, Mountain View, CA) into 96 well PCR plates and stored at -80˚C.
Single-cell PCR and sequencing
Immunoglobulin variable heavy and light chain variable regions (VH and VL) were RT-PCR
amplified using AmpliTaq360 Master Mix (Applied Biosystems) with conditions previously
described [55]. PCR products were purified (Qiagen, Valencia, CA) and sequenced with a Big-
Dye Sequencing kit (Applied Biosystems) on an ABI 3700 sequencer. VH and VL chain gene
rearrangements, clonal relatedness, UCA and intermediate ancestor (IA) inferences were
made using Cloanalyst [56].
Monoclonal antibody production
PCR-amplifed sequences were transiently expressed as previously described [55]. Briefly, lin-
ear expression cassettes were constructed by placing the PCR-amplified VH and VL chain
genes under the control of a CMV promoter along with an IgG constant region and poly A sig-
nal sequence. These linear expression cassettes were then co-transfected into 293T cells and
after three days the cell culture supernatants were harvested and concentrated.
For large scale expression, the VHDHJH and VLJL genes were synthesized (VH chain in the
IgG1 4A backbone) and transformed into DH5α cells (GeneScript, Piscataway, NJ). Plasmids
were expressed in Luria Broth, purified (Qiagen, Valencia, CA) and ~ 5x106 293i cells were
transfected with 1 mg of Ig (VH) and light (VL) chain genes using poly-ethylenimine (PEI) or
with 0.4mgs of heavy- and light chain-gene using ExpiFectamine™ (Life Technologies, Carls-
bad, CA) following the manufacturers protocol. After five days mAbs were concentrated, puri-
fied from the cell culture supernatant by an overnight incubation with Protein A beads and
buffer exchanged into PBS.
Plasma and mAb binding assays
High affinity 384-well microplates (Costar 3700) were coated overnight at 4˚C with 30ng/well
of protein in 0.1% Sodium Biocarbonate. For binding, a direct ELISA was performed in which
monoclonal antibodies (mAbs) beginning at 100ug/mL were diluted 3-fold in blocking buffer
and added to the plates for 1 hour. Antibody binding was detected using IgG-HRP (Rockland,
Limerick, PA) diluted 1:10,000 in azide-free blocking buffer. For the blocking ELISA, mAbs of
interest were diluted and added to the plate for one hour. Plates were washed and a biotiny-
lated mAb was added for one hour. Blocking was evaluated by adding streptavidin-HRP. The
direct binding and blocking ELISAs were developed using SureBlue Reserve TMB One Com-
ponent microwell peroxidase substrate (catalog no. 53-00-03; KPL) and the reactions were
stopped with 0.1% HCL. Plates were read on a plate reader (Molecular Devices) at 450 nm.
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Palivizumab (Synagis) (MedImmune, LLC; Gaithersburg, MD) was used as a negative control.
The plasma was screened with the binding Ab multiplex assay (BAMA) as previously
described. The antibody B12 was a gift from QBI and the Vaccine Research Program, Division
of AIDS, NIAID contract # HSN272201100023C.
Neutralization assays
Neutralization assays were performed in both TZM-bl and A3R5 cell lines as previously
described [23,32]. Data were reported as ID50 titers for plasma and IC50 titers for mAbs.
Yeast display epitope mapping of mAbs
Purified mAbs were epitope mapped on B.YU2gp120 core proteins (ΔV1, V2, V3 loops) dis-
played on S. cerevisiae as previously described [35,36]. Briefly, mAbs that bound B.YU2gp120
core protein were assayed for binding to 31 different B.YU2gp120 core proteins with point-
mutations and the wild type protein. Antigen-specific recognition was confirmed by the obser-
vation that mAbs did not show binding to non-displaying S. cerevisiae. Data was recorded as
the percent binding to a mutant relative to the wild type core proteins. The B12 binding data
in Figure 3 are from [36].
Surface plasmon resonance
Surface plasmon resonance was performed on a BIAcore 4000 instrument. The purified
recombinant mAb was immobilized to a CM5 sensor chip and envelope binding was measured
in real time with continuous flow of PBS (150mM NaCL, 0.005% surfactant P20 [pH 7.4] at
10–30 μl/min. Data was analyzed with BIAevaluation 4.1 software (BIAcore).
ADCC assays
ADCC mediated by the mAbs was assessed according to previously published procedures
[57,58]. Briefly, HIV-1 reporter virus used was a replication-competent infectious molecular
clone (IMC) designed to encode the HIV-1 env genes in cis within an isogenic backbone that
also expresses the Renilla luciferase reporter gene and preserves all viral open reading frames
[59]. CEM.NKRCCR5 cells (NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH:
CEM.NKR CCR5+ Cells from Dr. Alexandra Trkola [60] were infected with HIV-1 IMCs
encoding the subtype AE CM235 (accession number AF259954), B WITO (accession number
JN944948), and C Ce1086.c (accession number FJ444395) env genes within an NL4-3 back-
bone [59]. Whole PBMC from an HIV-seronegative donor with the heterozygous 158F/V
genotype for Fc-gamma receptor IIIa were used as effector cells at an effector cell to target cell
(E:T) ratio of 30:1. MAb A32 (James Robinson; Tulane University, New Orleans, LA), Palivizu-
mab (MedImmune, LLC; Gaithersburg, MD; used as negative control) and vaccine induced
mAbs were tested at a final concentration range of 10–0.039μg/ml using 4-fold serial dilutions.
All the conditions were evaluated after 6 hour incubation at 37˚C and 5%CO2. The ADCC
activity was reported as % specific killing calculated as [(RLU in control well − RLU in test
well)/ RLU of control well] ×100. The results were considered positive if ADCC activity was
15% specific killing. ADCC activities are reported either as the endpoint concentration (EC),
defined as the mAb concentration that intersects the positive cutoff of 15% specific killing, or
as positive area under the curve (pAUC), calculated by the trapezoidal rule using the values
15% specific killing.
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Design of the CH505 SOSIP.664 construct
To generate the autologous HIV-1 CH505 SOSIP.664 and clade B 92Br SOSIP.664 expression
constructs we followed established SOSIP design parameters [61]. Briefly, the SOSIP.664 tri-
mer was engineered with a disulfide linkage between gp120 and gp41 by introducing A501C
and T605C mutations (HxB2 numbering system) that covalently links the two subunits of the
heterodimer [61]. The I559P mutation was included in the heptad repeat region 1 (HR1) of
gp41 for trimer stabilization, and a deletion of part of the hydrophobic membrane proximal
external region (MPER), in this case residues 664–681 of the Env ectodomain [61]. The furin
cleavage site between gp120 and gp41 (508REKR511) was altered to 506RRRRRR511 to enhance
cleavage [61]. The resulting, codon-optimized CH505 SOSIP.664 env gene was obtained from
GenScript (Piscataway, NJ) and cloned into pVRC-8400 using Nhe1 and NotI restriction sites
and the tissue plasminogen activator signal sequence.
Expression and purification of Fabs for structural analysis
Fabs were expressed by transient transfection of HEK 293F suspension cells, using linear PEI
following the manufacturer’s suggested protocol. After 5 d, supernatants were clarified by cen-
trifugation and diluted twofold with 1x PBS buffer, and the protein isolated from the diluted
spernatant using CaptureSelect LC-Kappa (Hu) affinity matrix (Thermo Fisher Scientific,
Waltham, MA), according to manufacturer’s protocols. Fractions containing the protein of
interest were pooled, concentrated, and further purified by gel filtration chromatography
using a Superdex 200 analytical column (GE Healthcare Life Sciences, Pittsburgh, PA) in a
buffer of 2.5mM Tris, pH 7.5, 350mM NaCl, and 0.02% sodium azide.
Purification of Envs for analysis by negative stain EM
Each SOSIP.664 construct was transfected into 293F cells together with a plasmid encoding
the cellular protease, furin, at a 4:1 Env:furin ratio. The cells were allowed to express the soluble
trimer for 5–7 days. Culture supernatants were collected, cells removed by centrifugation at
3800 x g for 20 min, and the supernatant filtered with a 0.2 μm pore size filter. The soluble
SOSIP was purified by flowing the filtered supernatant over a lectin (Galanthus nivalis) affinity
chromatography column overnight at 4˚C. The lectin column was washed with 1x PBS, fol-
lowed with 1x PBS supplemented with 0.5 M NaCl, and proteins were eluted with 1 M methyl-
α-D-mannopyranoside dissolved in 1x PBS. The eluate was concentrated and loaded for
further purification onto a Superdex 200 10/300 GL column (GE Healthcare Life Sciences,
Pittsburgh, PA) prequilibrated in a buffer of 5 mM Hepes, pH 7.5, 150 mM NaCl and 0.02%
sodium azide for analysis by EM.
Electron microscopy
Purified SOSIP.664 trimer was incubated with a five molar excess of Fab at 4˚C for 1 hour. A
3 μL aliquot containing ~0.01 mg/ml of the complex was applied for 30 s onto a carbon coated
400 Cu mesh grid that had been glow discharged at 20 mA for 30 s, followed by negative stain-
ing with 2% uranyl formate for 20 s. Samples were imaged using a FEI Tecnai T12 microscope
operating at 120kV, at a magnification of 52,000x, resulting in a pixel size of 2.13 Å at the spec-
imen plane. Images were acquired with a Gatan 2K CCD camera using a nominal defocus of
1500 nm at 10˚ tilt increments, up to 50˚. The tilts provided additional particle orientations to
improve the image reconstructions.
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Negative stain image processing and 3D reconstruction
Particles were picked semi-automatically using EMAN2 [62] and put into a particle stack. Ini-
tial, reference-free, two-dimensional (2D) class averages were calculated and particles corre-
sponding to complexes (with one, two, or three Fabs bound) were selected into a substack for
determination of an initial model for the DH576: CH505 SOSIP.664 complex. The initial
model was calculated in EMAN2, imposing 3-fold symmetry, and subsequent refinement in
EMAN2 also imposed 3-fold symmetry. In total, 22,929 particles were included in the final
reconstruction. The resolution of the final model was determined using a Fourier Shell Corre-
lation (FSC) cut-off of 0.5.
Model fitting into the EM reconstructions
The cryo-ET structure of b12-bound gp120 trimer (PDB ID: 3DNL) [63] and an Fab model
were manually docked into the EM density and refined with the UCSF Chimera ‘Fit in map’
function [64]. The gp120 subunit of crystal structures with different Fabs were superposed on
other gp120 cores from the PDB by least-squares fitting in Coot [65]
Crystallization, structure determination, and refinement
The DH576 Fab was crystallized at 10–15 mg/mL. Crystals were grown in 96-well format
using hanging drop vapor diffusion and appeared after 24–48 h at 20˚C. Fab crystals were
obtained in the following conditions: 20% PEG 4000, 100mM Hepes, pH 7.0, 1M NaCl. Crys-
tals were harvested and cryoprotected by the addition of 20–25% glycerol to the reservoir solu-
tion and then flash-cooled in liquid nitrogen.
Diffraction data were obtained at 100 K from beam line 24-ID-C at the Advanced Photon
Source using a single wavelength. Datasets from individual crystals were processed with
HKL2000[66]. Molecular replacement calculations for the free Fab were carried out with PHA-
SER[67], using the variable domains of PGT135 [Protein Data Bank (PDB) ID 4JM2] and the
constant domains of VRC01 from the VRC01/gp120 complex [Protein Data Bank (PDB) ID
4LSS] as the starting models for molecular replacement.
Refinement was carried out with PHENIX[68], and all model modifications were carried
out with Coot[65]. During refinement, maps were generated from combinations of positional,
group B-factor, and TLS (translation/libration/screw) refinement algorithms. Secondary-
structure restraints were included at all stages for all Fabs. Structure validations were per-
formed periodically during refinement using the MolProbity server[69]. The final refinement
statistics are summarized in (S8 Table).
Statistical analysis
All statistical analysis was performed in SAS by the Duke Human Vaccine Institute statistical
team. The statistical test and p value are recorded where used.
Accession numbers
The EM reconstruction has been deposited in the Electron Microscopy Data Bank as EMD-
8573. The crystal structure of DH576 has been deposited in the Protein Data Bank as PDB
ID5UIX. The VH and VL chain genes described have been submitted to Genbank with acces-
sioning numbers KY499910-KY499949.
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Supporting information
S1 Fig. The RV144 and RV305 immunization regimens. The RV305 clinical trial
(NCT01435135) was a placebo-controlled double-blinded HIV-1 vaccine trial that occurred
six-eight years after the conclusion of RV144 (NCT00223080). RV144 vaccinees that received
the full RV144 immunization regimen and were HIV-1 seronegative were split into three
groups and boosted two times with either ALVAC-HIV + AIDSVAX B/E (Group I), AIDS-
VAX B/E (Group II), or ALVAC-HIV alone (Group III).
(EPS)
S2 Fig. Plasma neutralization of RV305 vaccinees. The plasma from two weeks after the sec-
ond boost in RV305 (wk. 26) from vaccinees boosted with AIDSVAX B/E (Group I), AIDS-
VAX B/E + ALVAC-HIV (Group II), or ALVAC-HIV (Group III) were screened in the A3R5
neutralization assay for neutralization of a panel of HIV-1 CRF_01 AE isolates. (A) ID50 in
A3R5 cells of each CRF_01 isolate per group (Grp I and III n = 23 and Grp II n = 24). (B) Indi-
vidual ID50 in A3R5 neutralization assay of vaccines from Group I and Group II when assayed
against the 11 CRF_01 AE viruses in (A). Red arrows denote vaccinees selected for antibody
isolation.
(EPS)
S3 Fig. Plasma gp120-specific IgG binding and neutralization of vaccine-recipients whose
vaccine-induced memory B cell repertoires were analyzed. The plasma of the four vaccinees
selected for antibody isolation were longitudinally assayed for (A) IgG binding to the autolo-
gous isolate AE.A244gp120Δ11 and heterologous isolate B.6240gp120Δ11 by Luminex and (B)
plasma neutralization of tier 1 and tier 2 viruses in the TZM-bl neutralization assay.
(EPS)
S4 Fig. The isolation of AE.A244gp120-specific antibodies from four RV305 vaccinees. AE.
A244gp120-double positive (upper right quadrant)memory B cells from two weeks after the
second RV305 boost (wk. 26) were antigen-specific single-cell sorted with fluorophore labeled
conjugates for RT-PCR.
(EPS)
S5 Fig. Relative to RV144 the gp120-specific antibodies after continued boosting had a
greater frequency of antibodies with Heavy Chain Complementary Determinant Region 3
(HCDR3) 22 amino acids. PBMCs from (A)14 RV135/144 vaccinees and (B) 4 RV305 vac-
cinees were antigen-specific single-cell sorted with fluorophore labeled conjugates. The VH/VL
chain genes were PCR-amplified and screened for Env-reactivity by ELISA. The VH chain
gene mutation frequency and HCDR3 lengths of 145 Env-reactive antibodies from RV135/144
and 242 Env-reactive antibodies from RV305 were analyzed with Cloanalyst[56].
(EPS)
S6 Fig. Env-reactive persistent clonal lineages identified in two vaccinees that were initi-
ated in RV144 vaccine-regimen and boosted 6–8 years later with the RV305 vaccine-regi-
men. PBMCs from two vaccinees that were immunized in both the RV144 and RV305 vaccine
trials were antigen-specific single-cell sorted with fluorophore labeled conjugates. The VH/VL
chain genes were PCR-amplified and analyzed with Cloanalyst [56].
(EPS)
S7 Fig. The long heavy chain determinant region 3 antibodies block the binding of the
CD4 bs bnAbs VRC01 and CH31 to AE.A244gp120. Antibodies were diluted 3-fold starting
at 100 ug/mL and assayed by ELISA for blocking of the CD4bs bnAbs VRC01 and CH31
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binding to AE.A244gp120.
(EPS)
S8 Fig. The long Heavy Chain Determinant Region 3 (HCDR3) CD4 binding site (bs) anti-
bodies do not potently mediate Antibody-Dependent Cellular Cytotoxicity (ADCC). The
RV305 antibodies were assayed for ADCC against WITO, 1086C and CM235 infected cells.
Shown is the antibody (A) end point concentration and (B) area under the curve. For compari-
son other CD4 bs and the C1/C2 antibody A32 are include.
(EPS)
S9 Fig. Negative stain EM of DH576 Fab in complex with the CH505 T/F SOSIP.664 tri-
mer. The Fourier shell correlation curve for the complex is shown along with the resolution
determined using FSC = 0.5.
(EPS)
S10 Fig. Superposition of B12 (purple) and DH576 (black) Fabs and an alignment of the
heavy chain sequences. (A) The HCDRH3 loop is highlighted to indicate the different confor-
mation of this loop for the two Fabs. The panel on the right shows a superposition with the
B12-gp120 complex and the arrow points to where the HCDR3 loop of DH576 clashes with
gp120 when the two antibodies are superimposed onto gp120 at the same angle. (B) A heavy
chain alignment of the DH576 unmutated common ancestor and naturally occurring DH576
clonal lineage members with the CD4 binding site bnAb B12. The  highlights conserved aro-
matic residues critical for B12 binding [40].
(EPS)
S11 Fig. Negative stained electron microscopy of DH583 in complex with 92Br SOSIP.664.
2D class averages of the complex are shown (top two rows) and unliganded trimer in the
closed form (bottom row).
(EPS)
S1 Table. The long heavy chain determinant region 3 antibodies isolated from post-RV305
by antigen-specific single-cell sorting. PBMCs from four vaccinees post-RV305 were antigen-
specific single-cell sorted, PCR-amplified and sequenced. The VH/VL chain gene sequences
were analyzed with Cloanalyst[56].
(EPS)
S2 Table. The boosts to RV144 vaccinees increased the frequency of long HCDR3 mAbs
compared to mAbs isolated from other HIV-1 human clinical trials. The frequency of
gp120-reactive (RV144 boosts) or gp140-reactive (HVTN 505 and GSK PRO HIV-002) mAbs
with HCDR3s 22 amino acids were compared using the Fisher’s Exact Test. The RV144
boosted vaccinees had a greater frequency of long HCDR3s compared to either the HVTN505
or GSK PRO HIV -002 clinical trials.
(EPS)
S3 Table. The long heavy chain determinant region 3 antibodies that were recombinantly
expressed in this study. The VH/VL chain gene sequences were analyzed with Cloanalyst[56].
(EPS)
S4 Table. Assaying the long heavy chain determinant region 3 antibodies for autologous
tier 1 neutralization. The antibodies were recombinantly expressed and assayed for neutrali-
zation of AE.92TH023 in the TZM-bl neutralization assay.
(EPS)
Vaccine-induced HIV-1 CD4 binding site neutralizing antibodies
PLOS Pathogens | DOI:10.1371/journal.ppat.1006182 February 24, 2017 16 / 21
S5 Table. Assaying the long heavy chain determinant region 3 CD4 bs antibodies for neu-
tralization of additional tier 2 CRF_01 AE isolates in the TZM-bl neutralization assay. The
antibodies were recombinantly expressed and assayed for neutralization of four tier 2 CRF_01
clade AE isolates in the TZM-bl neutralization assay.
(EPS)
S6 Table. Apparent affinity of the DH576 clonal lineage antibodies for clade AE CRF_01
Env binding. The unmutated common ancestor and intermediate antibody sequences were
inferred with Cloanalyst[56]. The antibodies were recombinantly expressed and assayed for
binding to Envs by surface plasmon resonance. Data shown are the dissociation constant (Kd).
(EPS)
S7 Table. Neutralization of the tier 2 CRF_01 AE.CNE8 virus by the Unmutated Common
Ancestor (UCA) of multiple CD4 binding site (bs) clonal lineages. The UCAs of the eight
CD4 bs clonal lineages were inferred with Cloanalyst[56]. The antibodies were recombinantly
expressed and assayed for neutralization in the TZM-bl neutralization assay.
(EPS)
S8 Table. Data collection and refinement statistics. Statistics for highest-resolution shell are
shown in parentheses.
(EPS)
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